title: Hormone therapy after endometrial cancer.
abstract: Endometrial carcinoma is often listed in data sheets as an absolute contraindication to hormone replacement therapy. However, observational studies have not shown an increased rate of recurrence or mortality. Thus, it is often used after stage I or II disease. Alternatives such as progestogens, tibolone, raloxifene, venlafaxine and herbal preparations are examined. The use of progestogens is under discussion because of potential adverse effects on the breast. Generally after treatment for endometrial cancer, current preference should be for low-dose oestrogen monotherapy rather than continuous combined therapy with progestogen addition in view of the increased risk of breast cancer and cardiovascular disease found with the latter regimen. It is important to note that risk factors for endometrial cancer such as hypertension, obesity, polycystic ovary syndrome and diabetes mellitus also increase the risk of cardiovascular disease. However, women must be informed about potential risks and the use of alternatives.
authors.affiliation: Department of Endocrinology and Menopause, Women's University Hospital University of Tuebingen Calwer Strasse 7, 72076 Tuebingen, Germany.
authors.forename: Alfred O
authors.initials: AO
authors.lastname: Mueck
authors.forename: Harald
authors.initials: H
authors.lastname: Seeger
mesh_terms: D017677:Age Distribution; D000368:Aged; D017024:Chemotherapy, Adjuvant; D003511:Cyclohexanols; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D005858:Germany / Q000453:epidemiology; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D015994:Incidence; D008875:Middle Aged; D009367:Neoplasm Staging; D009652:Norpregnenes / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
chemical_list: D003511:Cyclohexanols; D004967:Estrogens; D009652:Norpregnenes; D011372:Progestins; D020849:Raloxifene Hydrochloride; D000069470:Venlafaxine Hydrochloride; C027385:tibolone